 DURHAM, N.C.--BUSINESS WIRE--Aerie Pharmaceuticals, Inc. NASDAQ:AERI, an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its third quarter 2020 financial results will be released after the market closes on Thursday, November 5, 2020. Following the release, the Company will host a live conference c 